SHANGHAI & CAMBRIDGE, Mass. / Oct 18, 2024 / Business Wire / Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that members of the Company’s senior management team will participate in the following investor conferences in November and December 2024:
Goldman Sachs APAC Healthcare Corporate Day 2024
Time: November 5-8, 2024
Location: Hong Kong, Hong Kong
Jefferies London Healthcare Conference
Fireside Chat: Tuesday, November 19, 2024,1:30 p.m. GT
Location: Aldwych, London
Citi's 2024 Global Healthcare Conference
Time: December 3-5, 2024
Location: Miami, Florida
About Zai Lab
Zai Lab (NASDAQ: ZLAB; HKEX: 9688) is an innovative, research-based, commercial-stage biopharmaceutical company based in China and the United States. We are focused on discovering, developing, and commercializing innovative products that address medical conditions with significant unmet needs in the areas of oncology, immunology, neuroscience, and infectious disease. Our goal is to leverage our competencies and resources to positively impact human health in China and worldwide.
For additional information about Zai Lab, please visit www.zailaboratory.com or follow us at www.twitter.com/ZaiLab_Global.
| Last Trade: | US$29.03 |
| Daily Change: | -2.20 -7.04 |
| Daily Volume: | 241,828 |
| Market Cap: | US$3.230B |
September 01, 2025 August 13, 2025 August 07, 2025 | |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
